Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, results in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.
Type:
Grant
Filed:
April 11, 2018
Date of Patent:
January 9, 2024
Assignee:
Inhibrx, Inc.
Inventors:
Brendan P. Eckelman, Michael D. Kaplan, Katelyn M. Willis, Quinn Deveraux, John C. Timmer
Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
Type:
Grant
Filed:
August 5, 2020
Date of Patent:
January 2, 2024
Assignee:
AMGEN K-A, INC.
Inventors:
Joel E. Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
Type:
Grant
Filed:
May 21, 2018
Date of Patent:
December 26, 2023
Assignee:
Ichnos Sciences SA
Inventors:
Stanislas Blein, Romain Ollier, Darko Skegro, Samuel Hou
Abstract: It was found that association between CH1 and CL can be suppressed by substituting amino acids that exist on the interface between CH1 and CL with electrically-charged amino acids, and that formation of heterogeneous molecules is enabled more efficiently than by introducing knobs into holes mutations into CH3 domain.
Type:
Grant
Filed:
October 31, 2012
Date of Patent:
December 26, 2023
Assignee:
Chugai Seiyaku Kabushiki Kaisha
Inventors:
Taichi Kuramochi, Meiri Kawazoe, Naoka Hironiwa, Tomoyuki Igawa
Abstract: Described herein are novel anti-CD3 antibodies conjugated to folate and uses thereof treatment of diseases or conditions that would benefit from such conjugate are provided.
Type:
Grant
Filed:
November 2, 2016
Date of Patent:
December 26, 2023
Assignee:
Ambrx, Inc.
Inventors:
Harun Rashid, Feng Tian, Marco Gymnopoulos
Abstract: The present invention relates to the field of bioengineering, specifically to antibodies or their antigen-binding fragments, and to the use thereof. More particularly, the present invention relates to antibodies that bind specifically to CD47 and PD-L1. The invention also relates to a nucleic acid that codes for the given antibody or for the antigen-binding fragment thereof, to an expression vector, to a method of producing the antibody, and to a use of the aforementioned antibodies and compositions in cancer treatment.
Abstract: The present invention is relative to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or antibody fragment which includes a anti-IL-1RAP binding domain, polypeptides encoded by this nucleic acid molecule, isolated chimeric antigen receptor (CAR) molecule comprising such an antibody or antibody fragment, a vector comprising a nucleic acid molecule encoding a CAR, as well as a T cell comprising this vector. The present invention is also relative to the use of this T cell (autologous or allogeneic) expressing a CAR molecule to treat a proliferative disease in a mammal.
Type:
Grant
Filed:
November 14, 2018
Date of Patent:
December 12, 2023
Assignees:
ETABLISSEMENT FRANCAIS DU SANG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE, CENTRE HOSPITALIER UNIVERSITAIRE DE BESANCON, UNIVERSITE DE FRANCHE COMTE
Abstract: Antibodies that specifically bind to TIM 3 and antagonize TIM-3 function pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
Type:
Grant
Filed:
March 2, 2020
Date of Patent:
December 12, 2023
Assignee:
AGENUS INC.
Inventors:
Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Nicholas Stuart Wilson, Jeremy Dale Waight, Dennis John Underwood
Abstract: The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
Type:
Grant
Filed:
July 14, 2020
Date of Patent:
November 28, 2023
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Stefan Dengl, Guy Georges, Ralf Hosse, Inja Waldhauer, Christian Klein, Pablo Umana
Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.
Type:
Grant
Filed:
March 13, 2020
Date of Patent:
November 21, 2023
Assignee:
MACROGENICS, INC.
Inventors:
Leslie S. Johnson, Ling Huang, Gurunadh Reddy Chichili, Kalpana Shah, Chia-Ying Kao Lam, Stephen James Burke, Liqin Liu, Paul A. Moore, Ezio Bonvini, Bhaswati Barat
Abstract: The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the KD of 500 pM or less, as measured by surface plasmon resonance.
Type:
Grant
Filed:
June 4, 2020
Date of Patent:
November 21, 2023
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Nicholas J. Papadopoulos, Joel H. Martin, Eric Smith, Irene Noguera-Troise, Gavin Thurston
Abstract: Methods for producing Fabs and IgG bi-specific antibodies comprising expressing nucleic acids encoding designed residues in the CH1/CL interface are provided. Also provided are Fabs and IgG bi-specific antibodies produced according to the provided methods as well as nucleic acids, vectors and host cells encoding the same.
Type:
Grant
Filed:
December 14, 2017
Date of Patent:
November 21, 2023
Assignees:
Eli Lilly and Company, The University of North Carolina at Chapel Hill
Inventors:
Stephen John Demarest, Karen Jean Froning, Brian Arthur Kuhlman, Andrew Philip Leaver-Fay
Abstract: Provided herein are multispecific antibodies, e.g. bispecific antibodies, which are modified such that the desired chain pairing takes place and/or can be selected for. Specifically, this is achieved by using different dimerization domains for light chain pairing. Also disclosed herein are nucleic acids encoding for these antibodies, expression vectors comprising these nucleic acids, cells expressing them, and further to pharmaceutical compositions comprising the antibodies, as well as methods of isolating the antibodies.
Type:
Grant
Filed:
August 25, 2017
Date of Patent:
November 21, 2023
Assignee:
SANOFI
Inventors:
Ercole Rao, Christian Beil, Christian Lange, Katja Kroll, Wulf-Dirk Leuschner, Ingo Focken, Thomas Langer, Nadja Spindler
Abstract: The present invention provides antigen-binding polypeptides, including bi-specific antigen-binding polypeptides, that specifically bind to a first and a second target antigen with high affinity. The present invention also provides novel antigen-binding polypeptides that specifically bind to HER2 and antagonize HER2 activation. The invention also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen binding polypeptides. Methods of using antigen-binding polypeptide of the invention to treat disease, including cancer, are also encompassed by the invention.
Type:
Grant
Filed:
January 22, 2019
Date of Patent:
November 14, 2023
Assignee:
X-BODY, INC.
Inventors:
Yan Chen, Richard W. Wagner, Keming Zhang, Pascale Richalet
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to CD200. Also provided are uses of these proteins in therapeutic applications, such as the treatment of cancer and in conjunction with organ transplantation. Also provided are nucleic acids encoding the heavy and/or light chain variable regions (or heavy and/or light chains) of the antibodies, vectors comprising the nucleic acids, and cells that produce the antibodies.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
October 31, 2023
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Taneisha Ann-Tanara Mack, Douglas L. Sheridan, Tadas Panavas
Abstract: Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described.
Type:
Grant
Filed:
April 30, 2019
Date of Patent:
October 24, 2023
Assignee:
GENMAB A/S
Inventors:
Paul Parren, Patrick Van Berkel, Ewald Van Den Bremer
Abstract: The disclosure provides a tetra-specific antibody monomer having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first scFv domain at the N-terminal, a Fab domain, a Fc domain, a second scFv domain, and a third scFv at the C-terminal, wherein the first scFv domain, the Fab domain, the second scFv domain, and the third scFv domain each has a binding specificity against a different antigen. In one embodiment, the antigen is a tumor antigen, an immune signaling antigen, or a combination thereof. Multi-specific antibodies comprising the disclosed tetra-specific antibodies are also provided.
Inventors:
Yi Zhu, Ole Olsen, Dong Xia, David Jellyman, Katrina Bykova, Anne-Marie K. Rousseau, Bill Brady, Blair Renshaw, Brian Kovacevich, Yu Liang, Zeren Gao
Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
Abstract: The present invention relates to anti-HLA-DQ2.5 antibodies and its use for the treatment of celiac disease. The present invention provides anti-HLA-DQ2.5 antibodies that have been modified. The anti-HLA-DQ2.5 antibodies of the invention have binding activity to complexes formed by HLA-DQ2.5 and a gluten peptide, but have substantially no binding activity to complexes formed by HLA-DQ2.5 and an irrelevant peptide. Furthermore, the antibodies of the invention are shown to have inhibitory effects on T cell activation by gluten peptides.